At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 258 enrolled
Drug / intervention
Duloxetine hydrochloride +1 moredrug
Likely dose
Duloxetine hydrochloride 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Superiority Study of LY248686 Versus Placebo in the Treatment of Patients With Diabetic Peripheral Neuropathic Pain - Extension Phase
In Brief
A Phase 3 clinical trial evaluating Duloxetine hydrochloride for Diabetic Neuropathies. Completed, enrolled 258 participants across 25 sites.
Detailed Summary
The purpose of the study is to investigate safety and efficacy of duloxetine for patients with painful diabetic neuropathy at long-term use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Neuropathies
CountriesJapan
CollaboratorsShionogi
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartMar 2008
First PostedMar 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedMar 24, 2008
Enrollment StartMar 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 18.3 years ago
Interventions
Duloxetine hydrochloridedrug
Duloxetine 40 mg QD, PO, 1 year
Duloxetine hydrochloridedrug
Duloxetine 60 mg QD, PO, 1 year